Pasithea Therapeutics Corp. KTTA
Pasithea Therapeutics Corp. (Nasdaq: KTTA) is an oncology drug developer. Its lead program, PAS-004, is in Phase 1 for neurofibromatosis type 1 plexiform neurofibromas (NF1-PN) and MAPK pathway-driven advanced tumors. Its next catalyst on record is PAS-004: Complete first-in-human Phase 1 advanced cancer study (2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PAS-004 — Complete first-in-human Phase 1 advanced cancer study (2028). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PAS-004 (FIH Phase 1 advanced cancer study) | MAPK pathway-driven advanced solid tumors | small molecule | Phase 1 |
| PAS-004 (Phase 1/1b) | adult NF1 with symptomatic, inoperable or recurrent plexiform neurofibromas | small molecule | Phase 1 |
| PAS-001 | schizophrenia | unclear | Pre-clinical |
Recent results and decisions
- Nov 20, 2025positive Interim Phase 1: one unconfirmed partial response (-31.9% tumor reduction) in a BRAF V600E melanoma patient; DCR 71.4% (5/7) in BRAF-mutated and 42.8% (9/21) overall; all treatment-related AEs Grade 1-2, no DLTs.
Among 21 efficacy evaluable patients (as per RECIST1.1)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.